Merck loses bid to revive $2.54 billion patent verdict against Gilead

A U.S. appeals court on Wednesday dealt a major blow to Merck & Co Inc as it upheld a ruling that threw out a $2.54 billion jury verdict the drugmaker had won against Gilead Sciences Inc.